Danaher (DHR)
(Delayed Data from NYSE)
$190.46 USD
-2.83 (-1.46%)
Updated Sep 22, 2025 04:00 PM ET
After-Market: $190.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DHR 190.46 -2.83(-1.46%)
Will DHR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DHR
Can Danaher's Diagnostics Unit Sustain Growth Amid Lower Sales in China?
Danaher's Life Sciences Segment Shrinks: What's the Path Forward?
DHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Hologic's Breast Health Rebound in Motion: How to Play the Stock Now?
Danaher's Biotechnology Growth Picks Up: A Sign of More Upside?
Danaher Gains From Business Strength Amid Persisting Headwinds
Other News for DHR
Danaher price target lowered to $220 from $230 at BofA
Danaher price target lowered by $10 at BofA, here's why
Danaher (DHR) Receives a Buy from Bank of America Securities
B of A Securities Adjusts Danaher (DHR) Price Target to $220 | DHR Stock News
DHR's price falls by 1.02% on September 20, though its technical setup remains stable.